StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) KPIs and segments

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

KPIs & segments

Operating metrics and segments that drive Inhibikase Therapeutics's business

Coming soon

This tab will track the numbers specific to Inhibikase Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.

See a number that looks wrong?